Last reviewed · How we verify
ICP-332
At a glance
| Generic name | ICP-332 |
|---|---|
| Sponsor | Beijing InnoCare Pharma Tech Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria (PHASE2, PHASE3)
- Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis (PHASE2)
- Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis (PHASE2)
- ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis (PHASE3)
- ICP-332 in Subjects With Non-segmental Vitiligo (PHASE2, PHASE3)
- Phase I Study of ICP-332 in Healthy Subjects (PHASE1)
- Pharmacodynamic Blood Characteristics of ICP-332 in Patients With Moderate to Severe Atopic Dermatitis (PHASE2)
- A Phase I Randomized, Double-Blind, Placebo-Controlled, Parallel Group Clinical Study of ICP-332 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ICP-332 CI brief — competitive landscape report
- ICP-332 updates RSS · CI watch RSS
- Beijing InnoCare Pharma Tech Co., Ltd. portfolio CI